SOLUTIONS
EXPLORE FUNDS
CALCULATORS
fincash number+91-22-48913909Dashboard

Best Pharma Mutual Funds in India 2025

Updated on October 6, 2025 , 205458 views

The pharma sector is often called India’s “sunrise industry” – it not only meets domestic healthcare needs but also supplies medicines to the world. For investors, this sector has delivered resilience during crises (like Covid-19) and continues to show strong long-term growth potential.

Best Pharma Mutual Fund

That’s where Pharma Mutual Funds come in. These are sectoral funds that invest in pharmaceutical, healthcare, and allied companies, giving you exposure to one of India’s most promising industries.

But are they right for your Portfolio? Let’s explore.

What are Pharma Mutual Funds?

Pharma Mutual Funds are sectoral Equity Funds that invest primarily in companies from:

  • Pharmaceuticals
  • Biotechnology
  • Hospitals & healthcare services
  • Medical equipment & diagnostics

Since they are sector-specific, they carry higher risk than Diversified Funds, but also offer the chance to capture outsized gains when the sector outperforms.

Why Invest in Pharma Sector Funds?

Here’s why the Indian pharma industry is considered a strong bet:

1. India: The Pharmacy of the World

  • India supplies 20% of global generic medicines and is the largest vaccine manufacturer.
  • Nearly 40% of US generic drug demand is met by Indian companies.

2. Rising Domestic Demand

  • With growing middle-class income, lifestyle changes, and rising health awareness, healthcare spending in India is expected to rise sharply.
  • health insurance penetration is improving, further fuelling demand.

3. Government Push

  • Schemes like PLI (Production Linked Incentives) aim to boost domestic manufacturing of critical drugs and APIs.
  • Ayushman Bharat and other healthcare programmes are expanding access.

4. Export Growth & Innovation

  • Indian pharma is moving up the value chain with biosimilars, specialty drugs, and contract research.
  • Exports remain a major driver – particularly to regulated markets like the US and EU.

In short: Pharma funds allow you to benefit from both domestic consumption growth and global demand for cost-effective drugs.

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Selection Methodology used to find 10 funds

  • Keyword: “pharma”
  • Tags: fcpro
  • No Of Funds: 4
  • Funds suggested criteria is selected based on long terms returns and higher risk & assets under management (AUM) is high.

Best Pharma Sector Funds 2025

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2024 (%)
TATA India Pharma & Healthcare Fund Growth ₹30.3513
↓ -0.11
₹1,309-0.39.3-2.421.616.740.4
Nippon India Pharma Fund Growth ₹503.707
↓ -2.49
₹8,357-2.77.8-3.220.716.334
UTI Healthcare Fund Growth ₹288.709
↓ -0.95
₹1,1190.312.1023.816.642.9
SBI Healthcare Opportunities Fund Growth ₹427.289
↓ -0.26
₹3,963-2.210.33.824.718.642.2
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 8 Oct 25

Research Highlights & Commentary of 4 Funds showcased

CommentaryTATA India Pharma & Healthcare FundNippon India Pharma FundUTI Healthcare FundSBI Healthcare Opportunities Fund
Point 1Lower mid AUM (₹1,309 Cr).Highest AUM (₹8,357 Cr).Bottom quartile AUM (₹1,119 Cr).Upper mid AUM (₹3,963 Cr).
Point 2Established history (9+ yrs).Established history (21+ yrs).Oldest track record among peers (26 yrs).Established history (20+ yrs).
Point 3Not Rated.Top rated.Rating: 1★ (lower mid).Rating: 2★ (upper mid).
Point 4Risk profile: High.Risk profile: High.Risk profile: High.Risk profile: High.
Point 55Y return: 16.67% (upper mid).5Y return: 16.33% (bottom quartile).5Y return: 16.55% (lower mid).5Y return: 18.56% (top quartile).
Point 63Y return: 21.64% (lower mid).3Y return: 20.67% (bottom quartile).3Y return: 23.76% (upper mid).3Y return: 24.68% (top quartile).
Point 71Y return: -2.45% (lower mid).1Y return: -3.23% (bottom quartile).1Y return: 0.00% (upper mid).1Y return: 3.77% (top quartile).
Point 8Alpha: 3.78 (top quartile).Alpha: -4.31 (bottom quartile).Alpha: 0.79 (lower mid).Alpha: 2.04 (upper mid).
Point 9Sharpe: -0.39 (lower mid).Sharpe: -0.47 (bottom quartile).Sharpe: -0.15 (upper mid).Sharpe: -0.05 (top quartile).
Point 10Information ratio: 0.78 (top quartile).Information ratio: -0.53 (bottom quartile).Information ratio: 0.10 (lower mid).Information ratio: 0.38 (upper mid).

TATA India Pharma & Healthcare Fund

  • Lower mid AUM (₹1,309 Cr).
  • Established history (9+ yrs).
  • Not Rated.
  • Risk profile: High.
  • 5Y return: 16.67% (upper mid).
  • 3Y return: 21.64% (lower mid).
  • 1Y return: -2.45% (lower mid).
  • Alpha: 3.78 (top quartile).
  • Sharpe: -0.39 (lower mid).
  • Information ratio: 0.78 (top quartile).

Nippon India Pharma Fund

  • Highest AUM (₹8,357 Cr).
  • Established history (21+ yrs).
  • Top rated.
  • Risk profile: High.
  • 5Y return: 16.33% (bottom quartile).
  • 3Y return: 20.67% (bottom quartile).
  • 1Y return: -3.23% (bottom quartile).
  • Alpha: -4.31 (bottom quartile).
  • Sharpe: -0.47 (bottom quartile).
  • Information ratio: -0.53 (bottom quartile).

UTI Healthcare Fund

  • Bottom quartile AUM (₹1,119 Cr).
  • Oldest track record among peers (26 yrs).
  • Rating: 1★ (lower mid).
  • Risk profile: High.
  • 5Y return: 16.55% (lower mid).
  • 3Y return: 23.76% (upper mid).
  • 1Y return: 0.00% (upper mid).
  • Alpha: 0.79 (lower mid).
  • Sharpe: -0.15 (upper mid).
  • Information ratio: 0.10 (lower mid).

SBI Healthcare Opportunities Fund

  • Upper mid AUM (₹3,963 Cr).
  • Established history (20+ yrs).
  • Rating: 2★ (upper mid).
  • Risk profile: High.
  • 5Y return: 18.56% (top quartile).
  • 3Y return: 24.68% (top quartile).
  • 1Y return: 3.77% (top quartile).
  • Alpha: 2.04 (upper mid).
  • Sharpe: -0.05 (top quartile).
  • Information ratio: 0.38 (upper mid).

About the Fincash Research Team

At Fincash, our mission is to help investors make informed, confident decisions. With over 9 years in Mutual Fund distribution, our team blends deep industry expertise with a commitment to transparency, accuracy, and investor education.

Who We Are

AMFI Registration No.
112358
MCA CIN
U74999MH2016PTC282153
Location
Thane, Maharashtra, India
Experience
9+ years in Mutual Fund distribution

Our Expertise

  • Certified Mutual Fund Distributors with hands-on advisory experience.
  • Market analysts tracking performance, macro trends, and sectors.
  • Data specialists processing NAVs, allocations, and risk metrics from Morning Star.

Our Research Process

  • Data sourcing: SEBI-registered fund houses & verified third-party provider Morning Star
  • Screening: Returns, manager track record, expenses, sector mix, risk-adjusted metrics.
  • Expert review: Senior team members review every article and list for accuracy.
  • Updates: Regular refreshes so performance data reflects current market conditions.

Why Trust Us

  • Regulated & compliant: AMFI-registered and MCA-incorporated.
  • Investor-first: No pay-to-promote lists; suitability and performance drive coverage.
  • Education-focused: We simplify complex concepts for everyday investors.

Disclaimer

Content is for educational and informational purposes only and is not investment advice. Please consider your risk profile and consult a financial advisor before investing.

All the funds mentioned above are ideal, we are giving you detailed analysis of 3 funds.

1. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Research Highlights for TATA India Pharma & Healthcare Fund

  • Lower mid AUM (₹1,309 Cr).
  • Established history (9+ yrs).
  • Not Rated.
  • Risk profile: High.
  • 5Y return: 16.67% (upper mid).
  • 3Y return: 21.64% (lower mid).
  • 1Y return: -2.45% (lower mid).
  • Alpha: 3.78 (top quartile).
  • Sharpe: -0.39 (lower mid).
  • Information ratio: 0.78 (top quartile).
  • Top sector: Health Care.
  • Top bond sector: Cash Equivalent.
  • Equity-heavy allocation (~97%).
  • Largest holding Sun Pharmaceuticals Industries Ltd (~9.9%).

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund
Growth
Launch Date 28 Dec 15
NAV (08 Oct 25) ₹30.3513 ↓ -0.11   (-0.36 %)
Net Assets (Cr) ₹1,309 on 31 Aug 25
Category Equity - Sectoral
AMC Tata Asset Management Limited
Rating Not Rated
Risk High
Expense Ratio 2.17
Sharpe Ratio -0.39
Information Ratio 0.78
Alpha Ratio 3.78
Min Investment 5,000
Min SIP Investment 150
Exit Load 0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 20₹10,000
30 Sep 21₹13,118
30 Sep 22₹12,243
30 Sep 23₹14,936
30 Sep 24₹22,907
30 Sep 25₹22,051

TATA India Pharma & Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689
Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Oct 25

DurationReturns
1 Month -1%
3 Month -0.3%
6 Month 9.3%
1 Year -2.4%
3 Year 21.6%
5 Year 16.7%
10 Year
15 Year
Since launch 12%
Historical performance (Yearly) on absolute basis
YearReturns
2024 40.4%
2023 36.6%
2022 -8%
2021 19.1%
2020 64.4%
2019 5.5%
2018 -2.6%
2017 4.7%
2016 -14.7%
2015
Fund Manager information for TATA India Pharma & Healthcare Fund
NameSinceTenure
Rajat Srivastava16 Sep 240.96 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 31 Aug 25

Equity Sector Allocation
SectorValue
Health Care94.45%
Financial Services1.56%
Basic Materials1.44%
Asset Allocation
Asset ClassValue
Cash2.56%
Equity97.44%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA
10%₹130 Cr815,483
↓ -40,979
Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | CIPLA
7%₹91 Cr569,903
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP
5%₹67 Cr88,528
↓ -4,298
HealthCare Global Enterprises Ltd (Healthcare)
Equity, Since 31 Dec 18 | HCG
5%₹63 Cr942,453
Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | LUPIN
5%₹63 Cr330,887
Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | TORNTPHARM
5%₹60 Cr168,394
↑ 13,677
Aster DM Healthcare Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Dec 22 | ASTERDM
4%₹58 Cr956,991
Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEM
4%₹56 Cr106,435
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Jul 25 | 543220
4%₹53 Cr458,724
↑ 50,807
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
4%₹51 Cr83,315
↑ 21,175

2. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Research Highlights for Nippon India Pharma Fund

  • Highest AUM (₹8,357 Cr).
  • Established history (21+ yrs).
  • Top rated.
  • Risk profile: High.
  • 5Y return: 16.33% (bottom quartile).
  • 3Y return: 20.67% (bottom quartile).
  • 1Y return: -3.23% (bottom quartile).
  • Alpha: -4.31 (bottom quartile).
  • Sharpe: -0.47 (bottom quartile).
  • Information ratio: -0.53 (bottom quartile).
  • Top sector: Health Care.
  • Top bond sector: Cash Equivalent.
  • Equity-heavy allocation (~99%).
  • Largest holding Sun Pharmaceuticals Industries Ltd (~11.9%).

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund
Growth
Launch Date 5 Jun 04
NAV (08 Oct 25) ₹503.707 ↓ -2.49   (-0.49 %)
Net Assets (Cr) ₹8,357 on 31 Aug 25
Category Equity - Sectoral
AMC Nippon Life Asset Management Ltd.
Rating
Risk High
Expense Ratio 1.81
Sharpe Ratio -0.48
Information Ratio -0.53
Alpha Ratio -4.31
Min Investment 5,000
Min SIP Investment 100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 20₹10,000
30 Sep 21₹13,642
30 Sep 22₹12,514
30 Sep 23₹15,630
30 Sep 24₹23,190
30 Sep 25₹21,997

Nippon India Pharma Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689
Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Oct 25

DurationReturns
1 Month -1.6%
3 Month -2.7%
6 Month 7.8%
1 Year -3.2%
3 Year 20.7%
5 Year 16.3%
10 Year
15 Year
Since launch 20.2%
Historical performance (Yearly) on absolute basis
YearReturns
2024 34%
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
Fund Manager information for Nippon India Pharma Fund
NameSinceTenure
Sailesh Raj Bhan1 Apr 0520.43 Yr.
Kinjal Desai25 May 187.28 Yr.

Data below for Nippon India Pharma Fund as on 31 Aug 25

Equity Sector Allocation
SectorValue
Health Care99.48%
Asset Allocation
Asset ClassValue
Cash0.52%
Equity99.48%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
12%₹998 Cr6,256,349
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
7%₹613 Cr1,000,031
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLA
6%₹509 Cr3,200,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPIN
6%₹509 Cr2,683,991
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
6%₹494 Cr648,795
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
6%₹493 Cr3,916,074
Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427
4%₹305 Cr3,627,277
Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350
3%₹291 Cr2,886,684
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXO
3%₹254 Cr913,226
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
3%₹247 Cr1,320,549

3. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

  • Bottom quartile AUM (₹1,119 Cr).
  • Oldest track record among peers (26 yrs).
  • Rating: 1★ (lower mid).
  • Risk profile: High.
  • 5Y return: 16.55% (lower mid).
  • 3Y return: 23.76% (upper mid).
  • 1Y return: 0.00% (upper mid).
  • Alpha: 0.79 (lower mid).
  • Sharpe: -0.15 (upper mid).
  • Information ratio: 0.10 (lower mid).
  • Top sector: Health Care.
  • Top bond sector: Cash Equivalent.
  • Equity-heavy allocation (~99%).
  • Largest holding Sun Pharmaceuticals Industries Ltd (~9.4%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund
Growth
Launch Date 28 Jun 99
NAV (08 Oct 25) ₹288.709 ↓ -0.95   (-0.33 %)
Net Assets (Cr) ₹1,119 on 31 Aug 25
Category Equity - Sectoral
AMC UTI Asset Management Company Ltd
Rating
Risk High
Expense Ratio 2.26
Sharpe Ratio -0.15
Information Ratio 0.1
Alpha Ratio 0.79
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 20₹10,000
30 Sep 21₹13,129
30 Sep 22₹11,561
30 Sep 23₹14,305
30 Sep 24₹22,319
30 Sep 25₹21,898

UTI Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689
Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Oct 25

DurationReturns
1 Month -1.4%
3 Month 0.3%
6 Month 12.1%
1 Year 0%
3 Year 23.8%
5 Year 16.6%
10 Year
15 Year
Since launch 14.9%
Historical performance (Yearly) on absolute basis
YearReturns
2024 42.9%
2023 38.2%
2022 -12.3%
2021 19.1%
2020 67.4%
2019 1.2%
2018 -7.5%
2017 6.2%
2016 -9.7%
2015 12.4%
Fund Manager information for UTI Healthcare Fund
NameSinceTenure
Kamal Gada2 May 223.34 Yr.

Data below for UTI Healthcare Fund as on 31 Aug 25

Equity Sector Allocation
SectorValue
Health Care98.23%
Basic Materials1.12%
Asset Allocation
Asset ClassValue
Cash0.65%
Equity99.35%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA
9%₹105 Cr661,016
Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | CIPLA
6%₹64 Cr400,000
Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARM
5%₹60 Cr242,673
↑ 42,673
Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | LUPIN
5%₹51 Cr270,000
↑ 15,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY
4%₹45 Cr360,000
Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL
4%₹45 Cr70,039
↓ -10,244
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTIS
4%₹42 Cr465,000
Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | GLENMARK
4%₹42 Cr220,000
↑ 30,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP
4%₹40 Cr53,000
Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM
3%₹38 Cr72,000
↑ 17,000

4. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

  • Upper mid AUM (₹3,963 Cr).
  • Established history (20+ yrs).
  • Rating: 2★ (upper mid).
  • Risk profile: High.
  • 5Y return: 18.56% (top quartile).
  • 3Y return: 24.68% (top quartile).
  • 1Y return: 3.77% (top quartile).
  • Alpha: 2.04 (upper mid).
  • Sharpe: -0.05 (top quartile).
  • Information ratio: 0.38 (upper mid).
  • Top sector: Health Care.
  • Top bond sector: Cash Equivalent.
  • Equity-heavy allocation (~96%).
  • High-quality debt (AAA/AA ~100%).
  • Largest holding Sun Pharmaceuticals Industries Ltd (~10.9%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund
Growth
Launch Date 31 Dec 04
NAV (07 Oct 25) ₹427.289 ↓ -0.26   (-0.06 %)
Net Assets (Cr) ₹3,963 on 31 Aug 25
Category Equity - Sectoral
AMC SBI Funds Management Private Limited
Rating
Risk High
Expense Ratio 1.97
Sharpe Ratio -0.05
Information Ratio 0.38
Alpha Ratio 2.04
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 20₹10,000
30 Sep 21₹13,138
30 Sep 22₹12,251
30 Sep 23₹15,800
30 Sep 24₹23,614
30 Sep 25₹23,646

SBI Healthcare Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹481,656.
Net Profit of ₹181,656
Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Oct 25

DurationReturns
1 Month -1.2%
3 Month -2.2%
6 Month 10.3%
1 Year 3.8%
3 Year 24.7%
5 Year 18.6%
10 Year
15 Year
Since launch 15.3%
Historical performance (Yearly) on absolute basis
YearReturns
2024 42.2%
2023 38.2%
2022 -6%
2021 20.1%
2020 65.8%
2019 -0.5%
2018 -9.9%
2017 2.1%
2016 -14%
2015 27.1%
Fund Manager information for SBI Healthcare Opportunities Fund
NameSinceTenure
Tanmaya Desai1 Jun 1114.26 Yr.

Data below for SBI Healthcare Opportunities Fund as on 31 Aug 25

Equity Sector Allocation
SectorValue
Health Care90.36%
Basic Materials5.79%
Asset Allocation
Asset ClassValue
Cash3.85%
Equity96.15%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
11%₹431 Cr2,700,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
7%₹270 Cr440,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | 543220
6%₹242 Cr2,100,000
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | CIPLA
5%₹191 Cr1,200,000
Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LO3A
4%₹168 Cr270,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | LUPIN
4%₹159 Cr840,000
Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Jun 21 | TORNTPHARM
4%₹142 Cr400,000
↑ 80,000
Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND
3%₹138 Cr560,000
Fortis Healthcare Ltd (Healthcare)
Equity, Since 30 Apr 21 | FORTIS
3%₹137 Cr1,500,000
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
3%₹131 Cr700,000

Benchmark: The Nifty Pharma Index

Pharma Mutual Funds generally track or take cues from the Nifty Pharma Index.

Key Highlights:

  • Launched in 2005 by NSE.
  • Represents major listed pharma companies.
  • Includes top names like Sun Pharma, Dr. Reddy’s, Cipla, Divi’s Labs, Lupin, Aurobindo Pharma, etc.
  • The index gives investors a snapshot of the overall sector’s performance.

To more about index can be read on official website Nifty Pharma Index Document

Who Should Invest in Pharma Mutual Funds?

Pharma funds are not for everyone. They are suitable if you are:

  • An investor with high risk appetite who can handle sectoral Volatility.
  • Looking to diversify your portfolio with exposure to a defensive but growing industry.
  • A long-term investor (5+ years) seeking to benefit from structural growth trends in healthcare.

Not suitable for:

  • Conservative investors.
  • Those looking for short-term quick returns.

Pros & Cons of Investing in Pharma Funds

✅ Pros:

  • Strong long-term growth drivers (domestic + exports).
  • Defensive nature during downturns (people don’t stop consuming medicines).
  • India’s global dominance in generics provides steady demand.
  • Sector supported by government incentives.

❌ Cons:

  • High volatility as it depends on global regulations (like USFDA warnings).
  • Concentration risk – one sector only.
  • Currency fluctuations affect export-heavy companies.
  • Can underperform diversified funds during phases when pharma lags.

Unique Investor Angles to Consider

Here’s what most articles miss, but you should keep in mind:

Ageing Population = Permanent Demand

Globally, populations are ageing, particularly in developed countries. Indian companies are well-placed to serve this demand.

Shift Towards Wellness & Preventive Healthcare

Pharma is no longer just about medicines. Healthcare funds now capture hospitals, diagnostics, and preventive care businesses – expanding growth scope.

Regulatory Risk is Real

One USFDA ban can wipe out a stock’s value overnight. That’s why pharma funds spread risk across multiple companies.

Covid-19 Lesson

The pandemic proved how pharma can outperform when healthcare demand spikes – but it also showed the need to stay cautious about hype-driven rallies.

How to Invest in Pharma Sector Funds Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.

  2. Complete your Registration and KYC Process

  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

    Get Started

Public vs Private Healthcare: Why It Matters for Pharma Investors

India’s healthcare system is unique — while public hospitals account for only 30% of total hospital beds, the rest come from the private sector. This means the majority of patients depend on private care, which directly drives higher demand for medicines, diagnostics, and health insurance.

For pharma investors, this is critical. Unlike other industries, demand here is not cyclical — healthcare is a necessity. The more patients turn to private care, the more they rely on affordable medicines, making pharmaceutical companies long-term revenue generators.

The imbalance also highlights another important point: out-of-pocket expenditure in India is one of the highest in the world, around 48–50% of total healthcare spend. This forces households to prioritise low-cost drugs, generic medicines, and insurance-backed treatments — exactly the segments where Indian pharma companies have a competitive advantage.

Add to this the rise of medical tourism (expected to reach $13 billion+ by 2026), demand for speciality care in tier-2 cities, and a growing middle class that spends more on preventive healthcare. All of these trends ensure steady tailwinds for pharma companies and, by extension, pharma mutual funds.

This trend explains why pharma mutual funds are seen as a defensive bet — they combine healthcare demand certainty with the growth potential of India’s expanding private medical sector. In other words, the gap between public and private healthcare isn’t just a social challenge — it’s an investment signal, and one that smart investors can capture through pharma-focused fund.

Final Thoughts

Pharma Mutual Funds give investors a chance to tap into one of India’s strongest industries – with global leadership in generics, a growing domestic market, and government support. However, these are high-risk, high-reward funds. Don’t allocate more than 10–15% of your portfolio to sectoral funds, and always combine them with diversified mutual funds for stability.

If you believe in the long-term growth of healthcare and India’s role as the “Pharmacy of the World,” pharma funds can be a smart addition to your portfolio.

FAQs on Pharma Mutual Funds

Q1. Are pharma funds risky?

A: Yes, since they are concentrated sector funds. Suitable only for those who can take high risk.

Q2. How do pharma funds compare to diversified equity funds?

A: Diversified funds spread risk across sectors, pharma funds focus only on one. They can outperform in pharma bull runs but underperform otherwise.

Q3. What is the ideal investment horizon?

A: At least 5 years. Short-term Investing in sector funds is not recommended.

Q4. Are pharma funds good for SIPs?

A: Yes, SIPs help average out volatility in sectoral funds.

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 4.4, based on 37 reviews.
POST A COMMENT

Yogesh Kumar Juneja , posted on 5 Sep 21 12:30 PM

Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards

Shailendra, posted on 24 Jul 19 8:02 PM

Are largecap is best investment on longterm

1 - 2 of 2